Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Eur J Paediatr Neurol ; 49: 131-140, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38518417

RESUMO

AIM: To identify short-term effects of botulinum neurotoxin type A (BoNT) injections on gait and clinical impairments, in children with spastic cerebral palsy (CP), based on baseline gait pattern-specific subgroups. METHOD: Short-term effects of BoNT injections in the medial hamstrings and gastrocnemius were defined in a retrospective convenience sample of 117 children with CP (median age: 6 years 4 months; GMFCS I/II/III: 70/31/16; unilateral/bilateral: 56/61) who had received gait analyses before and 2 months post-BoNT. First, baseline gait patterns were classified. Statistical and meaningful changes were calculated between pre- and post-BoNT lower limb sagittal plane kinematic waveforms, the gait profile score, and non-dimensional spatiotemporal parameters for the entire sample and for pattern-specific subgroups. These gait waveforms per CP subgroup at pre- and post-BoNT were also compared to typically developing gait and composite scores for spasticity, weakness, and selectivity were compared between the two conditions. RESULTS: Kinematic improvements post-BoNT were identified at the ankle and knee for the entire sample, and for subgroups with apparent equinus and jump gait. Limbs with baseline patterns of dropfoot and to a lesser extent true equinus showed clear improvements only at the ankle. In apparent equinus, jump gait, and dropfoot, spasticity improved post-BoNT, without leading to increased weakness or diminished selectivity. Compared to typical gait, knee and hip motion improved in the crouch gait subgroup post-BoNT. CONCLUSION: This comprehensive analysis highlighted the importance of investigating BoNT effects on gait and clinical impairments according to baseline gait patterns. These findings may help identify good treatment responders.


Assuntos
Toxinas Botulínicas Tipo A , Paralisia Cerebral , Fármacos Neuromusculares , Humanos , Paralisia Cerebral/tratamento farmacológico , Paralisia Cerebral/fisiopatologia , Paralisia Cerebral/complicações , Toxinas Botulínicas Tipo A/administração & dosagem , Toxinas Botulínicas Tipo A/farmacologia , Toxinas Botulínicas Tipo A/uso terapêutico , Criança , Masculino , Feminino , Fármacos Neuromusculares/administração & dosagem , Fármacos Neuromusculares/farmacologia , Estudos Retrospectivos , Pré-Escolar , Fenômenos Biomecânicos/efeitos dos fármacos , Transtornos Neurológicos da Marcha/tratamento farmacológico , Transtornos Neurológicos da Marcha/etiologia , Transtornos Neurológicos da Marcha/fisiopatologia , Músculo Esquelético/fisiopatologia , Músculo Esquelético/efeitos dos fármacos , Adolescente , Resultado do Tratamento , Espasticidade Muscular/tratamento farmacológico , Espasticidade Muscular/fisiopatologia , Espasticidade Muscular/etiologia , Marcha/efeitos dos fármacos , Marcha/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA